Science & Enterprise subscription

Follow us on Twitter

  • An international group of universities and companies is designing a next-generation device to restore more natural… https://t.co/8cuc7GH22E
    about 15 hours ago
  • New post on Science and Enterprise: NIH Funds Natural Hearing Restoration Technology https://t.co/1Kd4DMGyAs #Science #Business
    about 15 hours ago
  • The commissioner of the Food and Drug Administration warned that the sharp rise in teen electronic cigarette use i… https://t.co/ki4NSp7zUI
    about 18 hours ago
  • New post on Science and Enterprise: FDA Chief Calls Teen Vaping an “Epidemic” https://t.co/jysDZCfTF8 #Science #Business
    about 18 hours ago
  • New contributed post on Science and Enterprise: https://t.co/tIrCNa7UiR Technology is Shaping the Future of Business Travel
    about 2 days ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

FDA Fast-Track Granted to Cancer Therapy Side-Effects Drug

Chemotherapy (National Institutes of Health)

(National Institutes of Health)

BioAlliance Pharma SA in Paris says its drug candidate to treat inflammation of the mucus membranes in the mouth, resulting from chemo- or radiation therapy to treat cancer, received fast-track status from the U.S. Food and Drug Administration. Validive, the drug’s brand name, is designed for patients with head and neck cancers.

Oral mucositis is an adverse effect of chemo- and radiation therapy, which can become severe and take up to eight weeks to heal, depending on the length of time exposed to radiation. The condition can result in pain, bleeding, or infection.

Valdive works by stimulating the alpha-2 adrenergic receptors that decrease the release of proteins encouraging inflammation of mucus membranes in the mouth. The company says its technology also increases the concentration of Valdive’s active ingredients in mucus and saliva.

BioAlliance Pharma says Valdive is currently in intermediate-stage clinical trials, with 180 head and neck cancer patients in the U.S. and Europe who received chemotherapy or radiation therapy, and who suffer from oral mucositis. In the trial, the drug is being tested against a placebo.

FDA’s fast track process expedites the review of drugs designed to address unmet medical needs. Fast track status provides new drug developers with more frequent meetings and correspondence with FDA officials. The company says Valdive also received orphan drug designation in Europe.

Read more:

*     *     *

Please share Science & Enterprise ...

Comments are closed.